

Rev 9/04

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Caroline A. Genco et al.
Filed : HEREWITH
For : IMMUNIZATION WITH PORPHYROMONAS GINGIVALIS
Attorney's Docket : PROTECTS AGAINST HEART DISEASE
Attorney's Docket : BU-096XX

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450 on _____.

By: _____

Registration No.
Attorney for Applicant(s)

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

It is desired to cite for the record in this application the
enclosed references listed on the attached copy of PTO Form #1449. The
paragraph(s) marked below are applicable to this Information Disclosure
Statement.

(1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached
Information Disclosure Statement is being filed within three
months of the filing date of the above identified national
application or within three months of the date of entry of the
national stage as set forth in 37 C.F.R. § 1.491 of the above
identified application. Accordingly, applicant(s) believes that
no fee or statement under 37 C.F.R. § 1.97(e) is required.

[] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

[] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.

[] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
[] a statement under 37 CFR § 1.97(e); or
[] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

[] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(p).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

[] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

[] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. §

Attorney Docket No.: BU-096XX
Filed: HEREWITH

1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Where the status of the application has changed, unknown to the applicant, such that the boxes checked are no longer applicable, the Commissioner is authorized to accept this submission with any additional fees required by that change charged to Deposit Account No. 23-0804.

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The art was cited in PCT International Search Report (copy enclosed) mailed December 27, 2004 in International Application No. PCT/US03/37013 filed November 18, 2003. Copies of the art have been transmitted by the International Bureau.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,
CAROLINE A. GENCO ET AL.

By: Holliday C. Heine
Holliday C. Heine, Ph.D.
Registration No. 34,346
Attorney for Applicant(s)
WEINGARTEN, SCHURGIN,
GAGNEBIN & LEOVICI LLP
Ten Post Office Square
Boston, Massachusetts 02109
Telephone: (617) 542-2290
Telecopier: (617) 451-0313

HCH/dkh/321558-1
Enclosure

(REV. 05/03)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	APPLICATION NO.
	INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		BU-096XX	10/535490
		APPLICANT: Caroline A. Genco et al.		
		FILING DATE HEREWITH	TC ART UNIT	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION/ ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE
		US					
		US					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	*DESHPANDE, R.G. ET AL., Invations strategies of the Oral Pathogen Porphyromonas Gingivalis: Implication for Carovascular Disease, Invasion and Metastasis, 1998, Vol. 18, No. 2, pp. 57-69
	*HERZBERG, M.C. ET AL., Dental Plaque, Platelets and Carovascular Diseases, Annals of Perodontology, the American Academy of Periodontology, July 1988, Vol. 3, No. 1, pp. 151-160.
	*LAMONT, R.J. ET AL., Life Below the Gum Line: Pathogenic Mechanisms of Porphyromonas Gingivallis, Microbiology and Molecular Biology Reviews, 1988, Vol. 62, No. 4, pp. 1244-1263.
	*LOESCHE, W.J. ET AL., Periodontal Disease as a Specific, Albeit Chronic, Infection: Diagnosis and Treatment, Clinical Microbiology Reviews, 2001, Vol. 14, No. 4, pp. 727-752.
	*CHEN, Z. ET AL., Protease-active Extracellular Protein Preparations for Porphyromonas Gingivalis, Abstracts of the General Meeting of the American Society for Microbiology, 2001, Vol. 101, pp. 117-118.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date: May 18, 2005

Page 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	APPLICATION NO.
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		BU-096XX	10/535490
		APPLICANT: Caroline A. Genco et al.	
		FILING DATE HEREWITH	TC ART UNIT

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

	*WHITAKER ET AL., Effect of an Essential Oil-containing Antiseptic Mouthrinse on Induction of Platelet Aggregation by Oral Bacteria In Vitro, Journal of Clinical Periodontology, 2000, Vol. 27, No. 5, pp. 370-373.
	*SHAPIRA ET AL., The Effects of Stress on the Inflammatory Response to Porphyromonas Gingivalis in a Mouse Subcutaneous Chamber Model, Journal of Periodontology, March 1999, Vol. 70, No. 3, pp. 289-292.
	*VASEL ET AL., Shared Antigen of Porphyromonas Gingivalis and Bacteroides Forsythus, Oral Microbiology and Immunology, 1996, Vol. 11, No. 4, pp. 226-235.
	*GENCO ET AL., A Peptide Domain on Gingipain R Which Confers Immunity Against Porphyromonas Gingivalis Infection in Mice, Infection and Immunity, September 1998, Vol. 66, No. 9, pp. 4108-4114.
	*GENCO ET AL., Influence of Immunization of Porphyromonas Gingivalis Colonization and Invasion in the Mouse Chamber Model, Infection and Immunity, April 1992, Vol. 60, No. 4, pp. 1447-1454.
	*HOUSTON ET AL., Response of Guinea Pigs to a Vaccine Containing a New Adjuvant (SAF) and Gram-Negative Bacteria, Laboratory Animal Science, February 1995, Vol 45, No. 1, pp. 58-66.
	*EVANS ET AL., Immunization with Porphyromonas (Bacteroides) Gingivalis Fimbriae Protects Against Periodontal Destruction, Infection and Immunity, July 1992, Vol. 60, No. 7, pp. 2926-2935.
	*PERSSON ET AL., Immunization Against Porphyromonas Gingivalis Inhibits Progression of Experimental Periodontitis in Nonhuman Primates, Infection and Immunity, March 1994, Vol. 62, No. 3, pp. 1026-1031.
	*FROLOV ET AL., In Vivo Exposure to Porphyromonas Gingivalis Up-regulates Nitric Oxide but Suppresses Tumour Necrosis Factor-Production by Cultured Macrophages, Immunology, March 1998, Vol 93, No. 3, pp. 323-328.
	*ZUBERY ET AL., Bone Resorption Caused by Three Periodontal Pathogens In Vivo in Mice is Mediated in Part by Prostaglandin, Infection and Immunity, September 1998, Vol. 66, No. 9, pp. 4158-4162.

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	